Aquatic Capital Management LLC Buys 29,189 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Aquatic Capital Management LLC lifted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 47.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,189 shares of the company’s stock after purchasing an additional 29,189 shares during the quarter. Aquatic Capital Management LLC owned about 0.11% of IDEAYA Biosciences worth $2,344,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in shares of IDEAYA Biosciences by 0.5% in the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock worth $2,919,000 after purchasing an additional 585 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after purchasing an additional 853 shares during the last quarter. Mariner LLC increased its holdings in shares of IDEAYA Biosciences by 9.8% in the 4th quarter. Mariner LLC now owns 9,775 shares of the company’s stock worth $251,000 after purchasing an additional 869 shares in the last quarter. Assetmark Inc. raised its stake in shares of IDEAYA Biosciences by 2.5% in the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company’s stock worth $1,163,000 after purchasing an additional 1,084 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of IDEAYA Biosciences during the fourth quarter valued at $35,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Up 3.9 %

IDYA stock opened at $19.75 on Tuesday. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The stock has a market cap of $1.73 billion, a P/E ratio of -5.98 and a beta of 0.51. The business’s 50-day moving average price is $17.98 and its 200-day moving average price is $23.29.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $7.00 million. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Stephens reaffirmed an “overweight” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.